Trial
NCT05152459
Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
City of Hope Medical Center
Collaborators
National Cancer Institute (NCI)
Condition
Recurrent Follicular Lymphoma
Intervention
Tazemetostat
Why stopped
Feasibility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-05-31